1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (708) 327-3326
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy [An erratum to this Article has been published in Cancer 2006;106(11):2530] †
Article first published online: 13 DEC 2004
DOI: 10.1002/cncr.20766
Copyright © 2004 American Cancer Society
Additional Information
How to Cite
Tanvetyanon, T. (2005), Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy [An erratum to this Article has been published in Cancer 2006;106(11):2530] . Cancer, 103: 237–241. doi: 10.1002/cncr.20766
- †
The opinions expressed herein do not necessarily reflect the views of the U.S. Department of Veterans Affairs.
Publication History
- Issue published online: 5 JAN 2005
- Article first published online: 13 DEC 2004
- Manuscript Revised: 24 SEP 2004
- Manuscript Accepted: 24 SEP 2004
- Manuscript Received: 28 JAN 2004
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , , , , , Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer, Prostate Cancer and Prostatic Diseases, 2012,
- 2, , , , , , , , The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer, Journal of Oncology, 2012, 2012, 1
- 3, , , , , , The Role of Distal Third Radius Dual Energy X-ray Absorptiometry (DXA) and Central DXA in Evaluating for Osteopenia and Osteoporosis in Men Receiving Androgen Deprivation Therapy for Prostate Cancer, Journal of Clinical Densitometry, 2012,
- 4, , , , , , , , , , , , Comparison of Rates and Risk Factors for Development of Osteoporosis and Fractures After Radical or Partial Nephrectomy, Urology, 2011, 78, 3, 614
- 5, , , Evaluation of Osteoporosis Risk Assessment in Veterans Receiving Androgen-Deprivation Therapy, The Consultant Pharmacist, 2011, 26, 1, 43
- 6, , Management of Side Effects of Androgen Deprivation Therapy, Endocrinology & Metabolism Clinics of North America, 2011, 40, 3, 655
- 7, Osteoporosis Related to Disease or Therapy in Patients With Cancer, Clinical Journal of Oncology Nursing, 2011, 15, 6, E90
- 8, , , Promoting calcium and vitamin D intake to reduce the risk of osteoporosis in men on androgen deprivation therapy for recurrent prostate cancer, Supportive Care in Cancer, 2011,
- 9, , , , , , , , , , , Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor, Journal of Bone and Mineral Research, 2011, 26, 10Direct Link:
- 10, , , , , , , Fracture Types and Risk Factors in Men With Prostate Cancer on Androgen Deprivation Therapy: A Matched Cohort Study of 19,079 Men, The Journal of Urology, 2010, 184, 3, 918
- 11, A note on age-related comorbidity, Archives of Gerontology and Geriatrics, 2009, 49, 1, 93
- 12, , , , , Management of complications of androgen deprivation therapy in the older man, Critical Reviews in Oncology/Hematology, 2009, 70, 3, 235
- 13, , , , , , , , , , , , Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer, BJU International, 2009, 103, 6Direct Link:
- 14, , , Managing Bone Loss in Men With Locally Advanced Prostate Cancer Receiving Androgen Deprivation Therapy, The Journal of Urology, 2008, 179, 2, 414
- 15, Bone Health in Men Receiving Androgen Deprivation Therapy for Prostate Cancer, The Journal of Urology, 2007, 177, 1, 17
- 16, , , , , Osteoporosis Management in Prostate Cancer Patients Treated with Androgen Deprivation Therapy, Journal of General Internal Medicine, 2007, 22, 9, 1305
- 17, , Biphosphonates in Advanced Prostate and Renal Cell Cancer – Current Status and Potential Applications, Urologia Internationalis, 2006, 76, 2, 97
- 18, , Improving the quality of clinical care for patients with osteoporosis, Expert Review of Pharmacoeconomics & Outcomes Research, 2006, 6, 6, 641
- 19, , , , , , Prevention and management of osteoporosis in men receiving androgen deprivation therapy: A survey of urologists and radiation oncologists, Urology, 2006, 68, 1, 126
- 20, , The Role of Bisphosphonates in Preventing Skeletal Complications of Hormonal Therapy, Urologic Clinics of North America, 2006, 33, 2, 191
- 21Prostate cancer treatment and osteoporosis risk, Nature Clinical Practice Oncology, 2005, 2, 2, 66
- 22, , , , , , , Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer, Acta Oncologica, 2005, 44, 7, 742